GlassScriptPhysician profile
Summaya A Latif
NPI 1356737118
$585.32
in general payments reported to CMS, 2019-2025
12 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $133 · 2024: $65.51 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $142.05 | 2025 | Evenity, Repatha, Tepezza |
| Novo Nordisk INC | $99.94 | 2022-2025 | Rybelsus, Ozempic |
| Medtronic, INC. | $57.53 | 2022-2025 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $57.32 | 2025 | Yorvipath |
| Tandem Diabetes Care, INC. | $47.52 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $47.27 | 2022-2025 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $32.46 | 2022 | |
| Mindray Ds USA, INC. | $26.11 | 2024 | Te7 Max, Te X |
| Horizon Therapeutics Plc | $24.26 | 2022 | |
| Beta Bionics, INC. | $19.55 | 2024 | Ilet Bionic Pancreas |
| Astrazeneca Pharmaceuticals LP | $16.31 | 2022 | |
| Dexcom, INC. | $15.00 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Summaya Latif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.